BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23852947)

  • 1. Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection.
    Wang L; Chen H; Fan C; Gong Z
    J Med Virol; 2013 Nov; 85(11):1907-12. PubMed ID: 23852947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
    Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
    J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus.
    Yu MM; Jiang Q; Ji Y; Wu KH; Ju LL; Tang X; Yang YF
    J Clin Virol; 2014 Sep; 61(1):55-60. PubMed ID: 24994007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
    Safadi R; Xie Q; Chen Y; Yin YK; Wei L; Hwang SG; Zuckerman E; Jia JD; Lopez P
    Liver Int; 2011 May; 31(5):667-75. PubMed ID: 21040410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.
    Chan HL; Chen YC; Gane EJ; Sarin SK; Suh DJ; Piratvisuth T; Prabhakar B; Hwang SG; Choudhuri G; Safadi R; Tanwandee T; Chutaputti A; Yurdaydin C; Bao W; Avila C; Trylesinski A
    J Viral Hepat; 2012 Oct; 19(10):732-43. PubMed ID: 22967105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
    Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
    Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
    Lai CL; Leung N; Teo EK; Tong M; Wong F; Hann HW; Han S; Poynard T; Myers M; Chao G; Lloyd D; Brown NA;
    Gastroenterology; 2005 Aug; 129(2):528-36. PubMed ID: 16083710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
    Lü W; Yang HH; Fan YM; Li T; Zhang LF; Mui C; Fan HW; Zhou BT; Liu ZY; Ng H; Liu XQ
    Chin Med J (Engl); 2013 Jun; 126(12):2333-6. PubMed ID: 23786949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B.
    Sulaiman A; Lesmana LA; Nafrialdi ; Helyanna
    Acta Med Indones; 2014 Jan; 46(1):38-43. PubMed ID: 24760807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.
    Fontana RJ; Hann HW; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Riker-Hopkins M; Brown N;
    Liver Transpl; 2001 Jun; 7(6):504-10. PubMed ID: 11443577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
    Sun J; Xie Q; Tan D; Ning Q; Niu J; Bai X; Fan R; Chen S; Cheng J; Yu Y; Wang H; Xu M; Shi G; Wan M; Chen X; Tang H; Sheng J; Dou X; Shi J; Ren H; Wang M; Zhang H; Gao Z; Chen C; Ma H; Jia J; Hou J
    Hepatology; 2014 Apr; 59(4):1283-92. PubMed ID: 24382690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
    Moon YM; Hwang SG; Kim BS; Rim KS; Cho M; Kim DJ; Han JY; Kim YS; Choi HS; Ahn SH
    Korean J Hepatol; 2007 Dec; 13(4):503-12. PubMed ID: 18159148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience.
    Panda C
    J Assoc Physicians India; 2013 Nov; 61(11):785-8. PubMed ID: 24974488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].
    Jia JD; Hou JL; Yin YK; Xu DZ; Tan DM; Niu JQ; Zhou XQ; Wang YM; Zhu LM; He YW; Ren H; Wan MB; Chen CW; Wu SM; Chen YG; Xu JZ; Wang QH; Wei L; Ma H
    Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):342-5. PubMed ID: 17524265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telbivudine in the treatment of chronic hepatitis B.
    Nash K
    Adv Ther; 2009 Feb; 26(2):155-69. PubMed ID: 19225726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B.
    He T; Bai Y; Cai H; Ou X; Liu M; Yi W; Jia J
    Hepatol Int; 2018 Mar; 12(2):118-125. PubMed ID: 29344772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.